Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BIIB – Biogen Inc.

Biogen Inc.
BIIB
$126.08
Name : Biogen Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $18,474,250,240.00
EPSttm : 10.12
finviz dynamic chart for BIIB
Biogen Inc.
$126.08
0.66%
$0.84

Float Short %

2.32

Margin Of Safety %

30

Put/Call OI Ratio

0.67

EPS Next Q Diff

0.97

EPS Last/This Y

3.62

EPS This/Next Y

0.64

Price

126.07

Target Price

170.22

Analyst Recom

2.08

Performance Q

-10.15

Relative Volume

0.66

Beta

0.15

Ticker: BIIB




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02BIIB131.20.720.6897180
2025-06-03BIIB131.90.720.6297764
2025-06-04BIIB131.860.720.3198942
2025-06-05BIIB130.380.720.3599349
2025-06-06BIIB133.140.720.1199996
2025-06-09BIIB134.180.710.1699886
2025-06-10BIIB135.510.700.31101071
2025-06-11BIIB133.070.700.38101366
2025-06-12BIIB132.320.700.29102045
2025-06-13BIIB130.660.700.61102299
2025-06-16BIIB131.040.680.4599961
2025-06-17BIIB126.540.680.89100123
2025-06-18BIIB126.570.680.66100137
2025-06-20BIIB127.050.680.98100301
2025-06-23BIIB124.80.670.7165684
2025-06-24BIIB126.30.680.6666513
2025-06-25BIIB127.360.670.3767147
2025-06-26BIIB126.970.670.9067478
2025-06-27BIIB126.090.670.9467900
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02BIIB131.12-23.1384.414.83
2025-06-03BIIB131.84-23.1374.914.83
2025-06-04BIIB131.86-23.1364.814.83
2025-06-05BIIB130.36-23.1342.414.83
2025-06-06BIIB133.12-23.1405.814.83
2025-06-09BIIB134.15-23.1379.514.83
2025-06-10BIIB135.48-23.1383.914.83
2025-06-11BIIB133.07-23.1329.514.83
2025-06-12BIIB132.31-23.1353.514.83
2025-06-13BIIB130.69-23.1340.714.83
2025-06-16BIIB131.06-23.1370.614.83
2025-06-17BIIB126.55-23.1297.814.83
2025-06-18BIIB126.54-23.1364.214.83
2025-06-20BIIB127.04-23.1372.214.83
2025-06-23BIIB124.80-23.1330.314.83
2025-06-24BIIB126.33-23.1388.814.83
2025-06-25BIIB127.35-23.1380.414.83
2025-06-26BIIB126.95-23.1358.414.83
2025-06-27BIIB126.07-23.1351.614.83
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02BIIB-4.39-1.402.28
2025-06-03BIIB-4.39-1.402.28
2025-06-04BIIB-4.39-1.402.28
2025-06-05BIIB-4.39-1.402.28
2025-06-06BIIB-4.39-1.402.28
2025-06-09BIIB-4.39-1.392.28
2025-06-10BIIB-4.35-1.392.28
2025-06-11BIIB-4.35-1.392.59
2025-06-12BIIB-4.35-1.392.59
2025-06-13BIIB-4.35-1.392.59
2025-06-16BIIB-4.35-1.312.59
2025-06-18BIIB-4.35-1.312.59
2025-06-20BIIB-4.35-1.312.59
2025-06-23BIIB-4.35-1.322.60
2025-06-24BIIB-3.91-1.322.60
2025-06-25BIIB-3.91-1.322.60
2025-06-26BIIB-3.91-1.322.32
2025-06-27BIIB-3.91-1.322.32
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

3.02

Avg. EPS Est. Current Quarter

4.06

Avg. EPS Est. Next Quarter

3.99

Insider Transactions

-3.91

Institutional Transactions

-1.32

Beta

0.15

Average Sales Estimate Current Quarter

2323

Average Sales Estimate Next Quarter

2277

Fair Value

163.58

Quality Score

90

Growth Score

58

Sentiment Score

43

Actual DrawDown %

73.1

Max Drawdown 5-Year %

-72.7

Target Price

170.22

P/E

12.45

Forward P/E

8.17

PEG

P/S

1.96

P/B

1.09

P/Free Cash Flow

7.58

EPS

10.13

Average EPS Est. Cur. Y​

14.83

EPS Next Y. (Est.)

15.47

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

15.73

Relative Volume

0.66

Return on Equity vs Sector %

-15.2

Return on Equity vs Industry %

-23.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

351.6
Biogen Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 7605
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
stock quote shares BIIB – Biogen Inc. Stock Price stock today
news today BIIB – Biogen Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BIIB – Biogen Inc. yahoo finance google finance
stock history BIIB – Biogen Inc. invest stock market
stock prices BIIB premarket after hours
ticker BIIB fair value insiders trading